» Articles » PMID: 36354946

Non-Mammalian Eukaryotic Expression Systems Yeast and Fungi in the Production of Biologics

Overview
Journal J Fungi (Basel)
Date 2022 Nov 10
PMID 36354946
Authors
Affiliations
Soon will be listed here.
Abstract

Biologics have become an important area of medical research generating therapeutics essential for the treatment of many disease states. Biologics are defined as biologically active compounds manufactured by living cells or through biological processes termed bioprocessing. Compared to small molecules which are chemically synthesised they are relatively complex and therapeutically specific molecules. Biologics include hormones, vaccines, blood products, monoclonal antibodies, recombinant therapeutic proteins, enzymes, gene and cellular therapies amongst others. For biologic production prokaryotic and eukaryotic cells (mammalian and non-mammalian) are used as expression systems. Eukaryotic expression systems offer many advantages over prokaryotic based systems. The manufacture of high-quality proteins for human clinical use via recombinant technologies has been achieved in yeast and filamentous fungal systems. Advances in bioprocessing such as genetic engineering, bioreactor design, continuous processing, and quality by design has allowed for increased productivity and higher yield in in these non-mammalian eukaryotic systems with protein translation similar to mammalian systems. The application of eukaryotic expressions systems for the manufacture of biologics of therapeutic importance are described herein.

Citing Articles

Molecular and Immunological Properties of a Chimeric Glycosyl Hydrolase 18 Based on Immunoinformatics Approaches: A Design of a New Anti- Vaccine.

da Cruz Freire J, Cardeal Dos Santos A, Coelho de Souza A, Oliveira A, Nicolete R, de Sousa B ACS Pharmacol Transl Sci. 2025; 8(1):78-96.

PMID: 39816796 PMC: 11729430. DOI: 10.1021/acsptsci.4c00341.


Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation.

Garvey M Pathogens. 2024; 13(6).

PMID: 38921759 PMC: 11206921. DOI: 10.3390/pathogens13060461.


Medical Device-Associated Healthcare Infections: Sterilization and the Potential of Novel Biological Approaches to Ensure Patient Safety.

Garvey M Int J Mol Sci. 2024; 25(1).

PMID: 38203372 PMC: 10778788. DOI: 10.3390/ijms25010201.


Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022.

Gu M, Sun S, You Q, Wang L Molecules. 2023; 28(24).

PMID: 38138431 PMC: 10745639. DOI: 10.3390/molecules28247941.


Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens.

Garvey M Infect Dis Rep. 2023; 15(4):454-469.

PMID: 37623050 PMC: 10454446. DOI: 10.3390/idr15040046.


References
1.
Tippelt A, Nett M . Saccharomyces cerevisiae as host for the recombinant production of polyketides and nonribosomal peptides. Microb Cell Fact. 2021; 20(1):161. PMC: 8374128. DOI: 10.1186/s12934-021-01650-y. View

2.
Spohner S, Schaum V, Quitmann H, Czermak P . Kluyveromyces lactis: An emerging tool in biotechnology. J Biotechnol. 2016; 222:104-16. DOI: 10.1016/j.jbiotec.2016.02.023. View

3.
Westman J, Franzen C . Current progress in high cell density yeast bioprocesses for bioethanol production. Biotechnol J. 2015; 10(8):1185-95. DOI: 10.1002/biot.201400581. View

4.
Jach M, Malm A . as an Alternative and Valuable Source of Nutritional and Bioactive Compounds for Humans. Molecules. 2022; 27(7). PMC: 9000428. DOI: 10.3390/molecules27072300. View

5.
Mohsen M, Zha L, Cabral-Miranda G, Bachmann M . Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017; 34:123-132. DOI: 10.1016/j.smim.2017.08.014. View